Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 73.6 kDa. The protein migrates as 100-170 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus CEACAM-5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Cynomolgus CEACAM-5, His Tag (Cat. No. CE5-C52H5) is more than 90% and the molecular weight of this protein is around 230-260 kDa verified by SEC-MALS.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd, The First Affiliated Hospital of Air Force Medical University | Liver Neoplasms; Colorectal Neoplasms | Details | |
MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
NEO-201 | NEO-201 | Phase 2 Clinical | Precision Biologics Inc, National Cancer Institute | Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Solid tumours; Ovarian Neoplasms; Intestinal Neoplasms; Cystadenocarcinoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Melanoma; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Intestinal Neoplasms; Rectal Neoplasms; Gastrointestinal Diseases; Colonic Neoplasms; Pancreatic Neoplasms; Brain Diseases; Brain Neoplasms; Colorectal Neoplasms; Brain metastases; Gastrointestinal Neoplasms; Intestinal Diseases | Details |
Tusamitamab Ravtansine | SAR-408701 | Phase 3 Clinical | Immunogen Inc | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Recombinant Saccharomyces cerevisiae-CEA | GI-6207 | Phase 2 Clinical | Globeimmune Inc | Head and Neck Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Colorectal Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.